AICDA and B-cell chronic lymphocytic leukemia: From these data, it can be concluded that AID-induced off-target damage significantly contributes to the acquisition of mutations in CLL and hence, the question arises whether inhibition of AID would delay disease onset, decelerate disease progression or synergize with treatment by decreasing mutation rates conferring drug resistance.